New inhaled drug for lung disease tested in healthy people first

NCT ID NCT07528703

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study tests a new inhaled drug called RC010 in 42 healthy adults in China. The main goal is to check if it is safe and how the body processes it. This drug is being developed for a serious lung condition called idiopathic pulmonary fibrosis (IPF), but this study does not involve people with the disease.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for IPF are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

idiopathic pulmonary fibrosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • China-Japan Friendship Hospital

    Beijing, Beijing Municipality, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••